A prediction study on radiation-induced second malignancies for IMRT treatment delivery

Sotirios Stathakis, Teboh Roland, Nikos Papanikolaou, Jinseng Li, Charlie Ma

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Low-level peripheral organ dose and its effect on second malignancies for patients undergoing radiation therapy have been reported in the literature. However, a comprehensive database outlining the treatment modalities, the tumor location, and a quantification of the overall relative risk of second malignancies is rather limited. In this work, we quantify the relative risks or percent likelihood of second malignancies for patients undergoing IMRT and conventional radiotherapy for four different tumor sites: breast, head and neck, lung, and prostate. We utilize Monte Carlo methods based on actual patient plans to compute the whole body effective dose equivalent for each plan and then deduce the percent likelihood of the occurrence of second malignancy. Based on an evaluation of over 30 actual patient plans and Monte Carlo simulations using 6, 10, and 18MV photon beam energies, we observed that the IMRT patients treated for head and neck cancer showed a 40% increase in risk for developing a second malignancy compared to those treated with conventional radiotherapy. The increase in risk for prostrate patients was 30% while the IMRT lung patients gave the highest relative risk almost tripling that observed in their conventionally treated counterparts. There was negligible difference in risk between breast patients undergoing IMRT treatment versus conventional therapy. The overall relative risk of radiation induced malignancy observed was below 6% in all treatment plans considered.

Original languageEnglish (US)
Pages (from-to)141-148
Number of pages8
JournalTechnology in Cancer Research and Treatment
Volume8
Issue number2
StatePublished - Apr 2009

Fingerprint

Second Primary Neoplasms
Radiation
Radiotherapy
Therapeutics
Monte Carlo Method
Lung
Head and Neck Neoplasms
Photons
Prostate
Neoplasms
Breast
Neck
Head
Databases
Breast Neoplasms

Keywords

  • Conventional radiotherapy
  • IMRT
  • Monte Carlo
  • Second malignancy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A prediction study on radiation-induced second malignancies for IMRT treatment delivery. / Stathakis, Sotirios; Roland, Teboh; Papanikolaou, Nikos; Li, Jinseng; Ma, Charlie.

In: Technology in Cancer Research and Treatment, Vol. 8, No. 2, 04.2009, p. 141-148.

Research output: Contribution to journalArticle

Stathakis, Sotirios ; Roland, Teboh ; Papanikolaou, Nikos ; Li, Jinseng ; Ma, Charlie. / A prediction study on radiation-induced second malignancies for IMRT treatment delivery. In: Technology in Cancer Research and Treatment. 2009 ; Vol. 8, No. 2. pp. 141-148.
@article{022d2789cbf945768ae664271952f212,
title = "A prediction study on radiation-induced second malignancies for IMRT treatment delivery",
abstract = "Low-level peripheral organ dose and its effect on second malignancies for patients undergoing radiation therapy have been reported in the literature. However, a comprehensive database outlining the treatment modalities, the tumor location, and a quantification of the overall relative risk of second malignancies is rather limited. In this work, we quantify the relative risks or percent likelihood of second malignancies for patients undergoing IMRT and conventional radiotherapy for four different tumor sites: breast, head and neck, lung, and prostate. We utilize Monte Carlo methods based on actual patient plans to compute the whole body effective dose equivalent for each plan and then deduce the percent likelihood of the occurrence of second malignancy. Based on an evaluation of over 30 actual patient plans and Monte Carlo simulations using 6, 10, and 18MV photon beam energies, we observed that the IMRT patients treated for head and neck cancer showed a 40{\%} increase in risk for developing a second malignancy compared to those treated with conventional radiotherapy. The increase in risk for prostrate patients was 30{\%} while the IMRT lung patients gave the highest relative risk almost tripling that observed in their conventionally treated counterparts. There was negligible difference in risk between breast patients undergoing IMRT treatment versus conventional therapy. The overall relative risk of radiation induced malignancy observed was below 6{\%} in all treatment plans considered.",
keywords = "Conventional radiotherapy, IMRT, Monte Carlo, Second malignancy",
author = "Sotirios Stathakis and Teboh Roland and Nikos Papanikolaou and Jinseng Li and Charlie Ma",
year = "2009",
month = "4",
language = "English (US)",
volume = "8",
pages = "141--148",
journal = "Technology in Cancer Research and Treatment",
issn = "1533-0346",
publisher = "Adenine Press",
number = "2",

}

TY - JOUR

T1 - A prediction study on radiation-induced second malignancies for IMRT treatment delivery

AU - Stathakis, Sotirios

AU - Roland, Teboh

AU - Papanikolaou, Nikos

AU - Li, Jinseng

AU - Ma, Charlie

PY - 2009/4

Y1 - 2009/4

N2 - Low-level peripheral organ dose and its effect on second malignancies for patients undergoing radiation therapy have been reported in the literature. However, a comprehensive database outlining the treatment modalities, the tumor location, and a quantification of the overall relative risk of second malignancies is rather limited. In this work, we quantify the relative risks or percent likelihood of second malignancies for patients undergoing IMRT and conventional radiotherapy for four different tumor sites: breast, head and neck, lung, and prostate. We utilize Monte Carlo methods based on actual patient plans to compute the whole body effective dose equivalent for each plan and then deduce the percent likelihood of the occurrence of second malignancy. Based on an evaluation of over 30 actual patient plans and Monte Carlo simulations using 6, 10, and 18MV photon beam energies, we observed that the IMRT patients treated for head and neck cancer showed a 40% increase in risk for developing a second malignancy compared to those treated with conventional radiotherapy. The increase in risk for prostrate patients was 30% while the IMRT lung patients gave the highest relative risk almost tripling that observed in their conventionally treated counterparts. There was negligible difference in risk between breast patients undergoing IMRT treatment versus conventional therapy. The overall relative risk of radiation induced malignancy observed was below 6% in all treatment plans considered.

AB - Low-level peripheral organ dose and its effect on second malignancies for patients undergoing radiation therapy have been reported in the literature. However, a comprehensive database outlining the treatment modalities, the tumor location, and a quantification of the overall relative risk of second malignancies is rather limited. In this work, we quantify the relative risks or percent likelihood of second malignancies for patients undergoing IMRT and conventional radiotherapy for four different tumor sites: breast, head and neck, lung, and prostate. We utilize Monte Carlo methods based on actual patient plans to compute the whole body effective dose equivalent for each plan and then deduce the percent likelihood of the occurrence of second malignancy. Based on an evaluation of over 30 actual patient plans and Monte Carlo simulations using 6, 10, and 18MV photon beam energies, we observed that the IMRT patients treated for head and neck cancer showed a 40% increase in risk for developing a second malignancy compared to those treated with conventional radiotherapy. The increase in risk for prostrate patients was 30% while the IMRT lung patients gave the highest relative risk almost tripling that observed in their conventionally treated counterparts. There was negligible difference in risk between breast patients undergoing IMRT treatment versus conventional therapy. The overall relative risk of radiation induced malignancy observed was below 6% in all treatment plans considered.

KW - Conventional radiotherapy

KW - IMRT

KW - Monte Carlo

KW - Second malignancy

UR - http://www.scopus.com/inward/record.url?scp=65949119342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65949119342&partnerID=8YFLogxK

M3 - Article

C2 - 19334795

AN - SCOPUS:65949119342

VL - 8

SP - 141

EP - 148

JO - Technology in Cancer Research and Treatment

JF - Technology in Cancer Research and Treatment

SN - 1533-0346

IS - 2

ER -